Background:Helicobacter pylori (H. pylori) gastritis could cause dyspepsia, and eradication is recommended as the first-line treatment. Patients who continuously have their symptoms under control > 6 months after eradication are defined as having H. pylori-associated dyspepsia (HPD), whereas patients who do not benefit from successful eradication are defined as having functional dyspepsia. Objectives: We assessed changes in dyspeptic symptoms after successful eradication of H. pylori by using a questionnaire. Methods: We studied H. pylori-infected dyspeptic participants with abdominal symptom scores > 4 points on the Global Overall Symptom (GOS) scoring items and received eradication therapy. We evaluated their symptoms using the GOS questionnaire before their eradications, at 1-month and at 1-year check-ups after eradication therapy. Results: Thirty dyspeptic participants (mean age 59.6 ± 15.3 years) answered every questionnaire. Fourteen participants (46.7%) had HPD, whereas 16 participants (53.3%) were non-HPD patients. The questionnaire at 1 month showed sensitivity of 64.3% (9/14) and specificity of 56.3% (9/16) for HPD. Approximately 60% of H. pylori-infected dyspepsia participants were identified as having HPD or non-HPD within 1 month after their eradications. Conclusions: Approximately 60% of HPD participants improved at 1 month after eradication. The questionnaire at 1 month helped diagnose HPD in advance and guided next treatment choice.

Journal Section:
Research Article
Keywords:
Functional dyspepsia, ROME IV, Functional gastrointestinal disorders, Global overall symptom, Eradication therapy
1.
Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal Disorders. Gastroenterology. 2016 May; 150(6): 1380–92.
2.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology. 2006 Apr; 130(5): 1466–79.
3.
Mahadeva S, Goh KL. Epidemiology of functional dyspepsia: a global perspective. World J Gastroenterol. 2006 May; 12(17): 2661–6.
4.
Suzuki H, Nishizawa T, Hibi T. Therapeutic strategies for functional dyspepsia and the introduction of the Rome III classification. J Gastroenterol. 2006 Jun; 41(6): 513–23.
5.
Sugano K. Should we still subcategorize helicobacter pylori-associated dyspepsia as functional disease? J Neurogastroenterol Motil. 2011 Oct; 17(4): 366–71.
6.
Suzuki H, Nishizawa T, Hibi T. Can Helicobacter pylori-associated dyspepsia be categorized as functional dyspepsia? J Gastroenterol Hepatol. 2011 Apr; 26 Suppl 3: 42–5.
7.
Suzuki H, Matsuzaki J, Hibi T. What is the difference between Helicobacter pylori-associated dyspepsia and functional dyspepsia? J Neurogastroenterol Motil. 2011 Apr; 17(2): 124–30.
8.
Tack J, Tally NJ, Camilleri M, et al. Functional Gastroduodenal Disorders. In: DA Drosman, editor. ROME III: The Functional Gastrointestinal Disorders. McLean, VA, USA; 2006, pp 419–86.
9.
Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol. 2007 Jan; 42(1): 1–15.
10.
Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ. 2002 Apr; 324(7344): 1012–6.
11.
Suzuki H, Nishizawa T, Hibi T. Helicobacter pylori eradication therapy. Future Microbiol. 2010 Apr; 5(4): 639–48.
12.
Suzuki H, Moayyedi P. Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol. 2013 Mar; 10(3): 168–74.
13.
Malfertheiner P, MOssner J, Fischbach W, Layer P, Leodolter A, Stolte M, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther. 2003 Sep; 18(6): 615–25.
14.
Sugano K, Tack J, Kuipers EJ, Graham DY, El-Omar EM, Miura S, et al.; faculty members of Kyoto Global Consensus Conference. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep; 64(9): 1353–67.
15.
Mock T, Yatscoff R, Foster R, Hyun JH, Chung IS, Shim CS, et al. Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Clin Biochem. 1999 Feb; 32(1): 59–63.
16.
Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, Barkun AN, Thomson AB, Mann V, et al. Validation of a 7-point Global Overall Symptom scale to measure the severity of dyspepsia symptoms in clinical trials. ­Aliment Pharmacol Ther. 2006 Feb; 23(4): 521–9.
17.
Sakurai K, Nagahara A, Inoue K, Akiyama J, Mabe K, Suzuki J, et al. Efficacy of omeprazole, famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms: an omeprazole-controlled randomized study (J-FOCUS). BMC Gastroenterol. 2012 May; 12(1): 42.
18.
van Zanten SV, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled “ENTER” trial. Am J Gastroenterol. 2006 Sep; 101(9): 2096–106.
19.
Blum AL, Talley NJ, O’Moráin C, van Zanten SV, Labenz J, Stolte M, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med. 1998 Dec; 339(26): 1875–81.
20.
Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 1999 Oct; 341(15): 1106–11.
21.
Miwa H, Hirai S, Nagahara A, Murai T, Nishira T, Kikuchi S, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2000 Mar; 14(3): 317–24.
22.
Kamada T, Haruma K, Hata J, Kusunoki H, Sasaki A, Ito M, et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther. 2003 Jul; 18(2): 245–52.
23.
Azuma T, Ito Y, Suto H, Ohtani M, Dojo M, Muramatsu A, et al. The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan. Aliment Pharmacol Ther. 2001 Jun; 15(6): 805–11.
24.
Suzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol. 2005 Nov; 20(11): 1652–60.
25.
Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2001;(1):CD002096.
26.
Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter. 2007 Oct; 12(5): 541–6.
27.
Peng YC, Huang LR, Shyu CL, Cheng CC, Ho SP. Interaction of omeprazole and Helicobacter pylori-induced nuclear factor-κB activation and mediators in gastric epithelial cells. J Chin Med Assoc. 2014 Nov; 77(11): 567–72.
28.
Kim SH, Kim JW, Byun J, Jeong JB, Kim BG, Lee KL. Plasma ghrelin level and plasma ghrelin/obestatin ratio are related to intestinal metaplasia in elderly patients with functional dyspepsia. PLoS One. 2017 Apr; 12(4): e0175231.
29.
Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, et al. Impaired production of gastric ghrelin in chronic gastritis ­associated with Helicobacter pylori. J Clin Endocrinol Metab. 2005 Jan; 90(1): 10–6.
© 2019 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2019
You do not currently have access to this content.